BIIB092 in Primary Tauopathies: CBS, nfvPPA, sMAPT, and TES

Summary

A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel Cohort Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of Intravenously Infused BIIB092 in Patients with Four Different Primary Tauopathy Syndromes

Timeline

Start

2018-09-12

Primary completion

2019-12-13

Completion

2019-12-13

Outcome

Outcome not reported

Stopped: “BIIB092 program discontinued”

Drugs

Indications